Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Indiana

    Search
    Indiana
    Show Map
    Map View
    Indiana
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      178 Clinical Paid Trials near Indiana

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Selinexor + Temozolomide for Recurrent Glioblastoma

      Orland Park, Illinois
      This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Pregnant, Severe COVID-19, Others
      Must Not Be Taking:Bevacizumab, Dacarbazine

      97 Participants Needed

      HB0036 for Advanced Cancer

      Lafayette, Indiana
      This trial is testing a new drug called HB0036 in patients with advanced solid tumors, including NSCLC. The goal is to determine if the drug is safe and effective in treating these cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Autoimmune Disease, Active Infection, Others
      Must Not Be Taking:Antibiotics, Corticosteroids

      80 Participants Needed

      AFX3772 Vaccine for Pneumococcal Infections

      Louisville, Kentucky
      This trial tests a new vaccine called AFX3772 in healthy infants to prevent pneumococcal disease. The vaccine aims to help their immune systems recognize and fight off the bacteria that cause this disease.
      No Placebo Group

      Trial Details

      Trial Status:Completed
      Trial Phase:Phase 2
      Age:42 - 90

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Allergies, Bleeding Disorders, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Immunoglobulins, Others

      388 Participants Needed

      Selumetinib Granules for Neurofibromatosis

      Indianapolis, Indiana
      This trial tests selumetinib granules in children aged 1 to 7 years with inoperable NF1-related tumors. The medication works by blocking signals that make the tumors grow. The study aims to find the right dose and check if it's safe and effective.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:1 - 6

      Key Eligibility Criteria

      Disqualifiers:Malignant Glioma, Cardiovascular Disease, Others
      Must Not Be Taking:MEKi, Herbal Supplements

      36 Participants Needed

      Fluticasone Nasal Spray for Eustachian Tube Dysfunction

      Indianapolis, Indiana
      This trial tests a new nasal spray system for patients with chronic Eustachian tube dysfunction. The spray uses your breath to push medicine deeper into your nasal passages, aiming to improve treatment effectiveness.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Otologic Surgery, Head Cancer, Others
      Must Be Taking:Intranasal Steroids

      80 Participants Needed

      BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

      Indianapolis, Indiana
      BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Resistant Mutations, Interstitial Lung Disease, Others
      Must Be Taking:EGFR TKIs

      200 Participants Needed

      4D-150 for Age-Related Macular Degeneration

      Carmel, Indiana
      Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Uveitis, Photodynamic Therapy, Others
      Must Be Taking:Anti-VEGF

      215 Participants Needed

      BA3071 + Nivolumab for Cancer

      Dyer, Indiana
      The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, CNS Metastasis, HIV, Others

      320 Participants Needed

      Selinexor + Radiation for Brain Cancer

      Louisville, Kentucky
      This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 21

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Infection, Organ Transplant, Others
      Must Not Be Taking:Investigational Drugs, Anti-cancer Agents

      132 Participants Needed

      STMC-103H for Allergies

      Indianapolis, Indiana
      This trial is testing a new treatment called STMC-103H to see if it can help prevent allergic diseases in young children. The study focuses on babies and infants who are at risk of developing allergies. The treatment aims to improve their immune system's response to allergens, potentially reducing conditions like atopic dermatitis.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 14

      Key Eligibility Criteria

      Disqualifiers:Congenital Abnormalities, Immune Deficiency, Others
      Must Not Be Taking:Systemic Antibiotics

      264 Participants Needed

      Tovorafenib + Pimasertib for Cancer

      Indianapolis, Indiana
      This trial is testing Tovorafenib, a drug that blocks proteins needed for cancer cell growth, in patients aged 12+ with hard-to-treat melanoma or other solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Activating Mutation, CSR, RVO, Others
      Must Not Be Taking:RAS-RAF-MEK-ERK Inhibitors

      168 Participants Needed

      Asciminib for Pediatric Chronic Myeloid Leukemia

      Indianapolis, Indiana
      The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:1 - 17

      Key Eligibility Criteria

      Disqualifiers:T315I Mutation, Cardiac Abnormality, Pancreatitis, Others
      Must Be Taking:TKIs

      44 Participants Needed

      UX701 Gene Therapy for Wilson Disease

      Indianapolis, Indiana
      This trial tests UX701, a new treatment for patients with Wilson disease. It aims to help these patients better control their copper levels, preventing harmful effects. The study will evaluate the safety and effectiveness of UX701 over time.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Liver Transplant, Advanced Liver Disease, Others
      Must Be Taking:Copper Chelators, Zinc

      82 Participants Needed

      TAK-186 for Advanced Cancer

      Indianapolis, Indiana
      This trial is testing a new drug called TAK-186 to see if it is safe and effective for adults with advanced cancers that cannot be removed by surgery. The drug works by targeting a specific protein on cancer cells to help stop their growth.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Cardiovascular Disease, Gastrointestinal Disorders, Others
      Must Not Be Taking:Immune-suppressive Drugs, Corticosteroids

      97 Participants Needed

      XB2001 + Chemotherapy for Pancreatic Cancer

      Goshen, Indiana
      This trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT), in combination with ONIVYDE + LV + 5-FU chemotherapy regimen in patients with advanced pancreatic cancer and to determine the recommended dose for the subsequent Phase 2 study. The phase 2 portion will be implemented with the maximum established tolerated dose (MTD) of XB2001. The target enrollment in the phase 2 portion is 60 patients which will be randomized on a 1:1 basis to XB2001 plus ONIVYDE + LV + 5-FU (Arm 1) or placebo plus ONIVYDE + LV + 5-FU (Arm 2).

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Heart Failure, Others
      Must Not Be Taking:CYP3A4 Inducers, UGT1A1 Inhibitors

      76 Participants Needed

      Alkaline Buffer Challenge for Asthma

      Indianapolis, Indiana
      Airway pH imbalances cause numerous adverse physiological changes within the airways, including hyperreactivity, cough, bronchoconstriction, ciliopathy, decreased response to bronchodilators, bacterial growth, nitrosative/oxidative stress, neutrophilic/eosinophilic inflammation, and cell death. Airway pH is known to be low (acidic) in chronic and acute pulmonary diseases. The gold standard approach to measuring airway pH is to bronchscopically obtain epithelial cell lining fluid using protected brush sampling. The expense and invasive nature of this approach is a barrier to fully characterizing the role of airway pH in the health and disease. In this study, we will evaluate non-invasive clinical methods that can be done using equipment standard in clinical pulmonary function laboratories for measuring airway pH.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Mechanical Ventilation, Continuous Oxygen Therapy, Others

      150 Participants Needed

      Diagnostic Testing for Pediatric Leukemia

      Indianapolis, Indiana
      This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:< 22

      Key Eligibility Criteria

      Disqualifiers:Over 22 Years, Others

      960 Participants Needed

      Radiosurgery + Olaparib + Immunotherapy for Breast Cancer Brain Metastases

      Indianapolis, Indiana
      This trial is testing a combination of focused radiation, olaparib, and immunotherapy for patients with specific types of breast cancer that have spread to the brain. The treatment aims to kill cancer cells, make them more vulnerable, and boost the body's immune response. Olaparib has shown promising results in various cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Leptomeningeal Carcinomatosis, Brain Injury, Autoimmune Disorders, Others
      Must Be Taking:Olaparib

      41 Participants Needed

      AB-101 + Immunotherapy for Non-Hodgkin's Lymphoma

      Louisville, Kentucky
      AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      45 Participants Needed

      DSP107 + Atezolizumab for Solid Tumors

      Indianapolis, Indiana
      Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Autoimmune Disease, Liver Disease, Others
      Must Not Be Taking:Immunosuppressants, Immunostimulants, Atezolizumab, Others

      125 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Trial

      CAR T Cell Therapy for Large B-Cell Lymphoma

      Louisville, Kentucky
      This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Involvement, Thyroid Disorder, Active Malignancies, Others

      160 Participants Needed

      AVM0703 for Lymphoma

      Louisville, Kentucky
      This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 95

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Diabetes, Infections, Others
      Must Not Be Taking:Antidepressants

      144 Participants Needed

      OBI-3424 for T-Cell Acute Lymphoblastic Leukemia

      Louisville, Kentucky
      This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infections, Recent Transplant, Others
      Must Not Be Taking:Chemotherapy, Investigational Agents

      67 Participants Needed

      Bosutinib for Chronic Myeloid Leukemia

      Louisville, Kentucky
      This trial tests bosutinib, a daily oral medication, in children with a type of leukemia. It aims to find a safe dose and see how well it works in those newly diagnosed or who haven't responded to other treatments. Bosutinib helps by blocking proteins that cancer cells need to grow. Bosutinib is a type of medication used for treating leukemia, especially in cases not responding to other treatments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:1 - 17

      Key Eligibility Criteria

      Disqualifiers:Acute Lymphoblastic Leukemia, Cardiac Disease, Infections, Others
      Must Be Taking:Tyrosine Kinase Inhibitors

      60 Participants Needed

      SAMe for Liver Cirrhosis

      Indianapolis, Indiana
      The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hepatitis, HIV, Renal Failure, Others
      Must Not Be Taking:Antipsychotics

      196 Participants Needed

      CCS1477 for Blood Cancers

      Indianapolis, Indiana
      A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Severe Diseases, Uncontrolled Illness, Others
      Must Not Be Taking:Chemotherapy, Statins, CYP3A4 Inhibitors, Others

      250 Participants Needed

      Ziftomenib for Relapsed/Refractory Acute Myeloid Leukemia

      Indianapolis, Indiana
      This trial is testing ziftomenib, a new drug, in patients with difficult-to-treat acute myeloid leukemia (AML). The drug works by blocking a protein interaction that cancer cells need to grow.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, CNS Leukemia, Others
      Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers

      199 Participants Needed

      Vorinostat for Graft-versus-Host Disease Prevention

      Indianapolis, Indiana
      The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:3 - 39

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, HIV, Hepatitis, Others
      Must Not Be Taking:Valproic Acid

      43 Participants Needed

      Quizartinib for Acute Myeloid Leukemia

      Indianapolis, Indiana
      Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:1 - 21

      Key Eligibility Criteria

      Disqualifiers:CNS Relapse, APL, HIV, Others
      Must Not Be Taking:Chemotherapy, Radiation, Immunotherapy, Others

      65 Participants Needed

      Navtemadlin +/− Immunotherapy for Skin Cancer

      Louisville, Kentucky
      This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Immunosuppression, Organ Transplant, Others

      115 Participants Needed

      123456

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Clinical Trials near Indiana

      Top Clinical Trials near Elkhart, IN

      139 Clinical Trials near Granger, IN

      197 Clinical Trials near Elwood, IN

      128 Clinical Trials near Crown Point, IN

      Top Clinical Trials near Louisiana

      Top Clinical Trials near Arizona

      Top Clinical Trials near Missouri

      Top Clinical Trials near Illinois

      Top Clinical Trials near Connecticut

      Top Clinical Trials near Colorado

      Top Clinical Trials near Fairbanks, AK

      By Trial

      DaRT Seeds for Skin Cancer

      Inhaler Trainer for Asthma and COPD

      Guided CRT Implantation for Chronic Heart Failure

      ctDNA Testing for Oropharyngeal Cancer

      CD30 CAR T-Cell Therapy for Lymphoma

      Temperature Control for Heat Stress

      Pembrolizumab + Sunitinib for Thymic Cancer

      Hyperpolarized Xenon-129 MRI for Electronic Cigarette Use Effects on Lungs

      Radioimmunotherapy for Multiple Myeloma

      QTX3046 + Cetuximab for Solid Tumors

      Vinblastine/Prednisone vs. Cytarabine for Histiocytosis

      Ensartinib for Cancer

      Related Searches

      Top Eoe Clinical Trials

      BGB-16673 for Chronic Lymphocytic Leukemia

      Alpelisib + Tucatinib for Breast Cancer

      Thrombectomy for Stroke

      Splenic Artery Embolization for Splenic Injuries

      Zilovertamab Vedotin for Bladder Cancer

      Amivantamab + Docetaxel for Non-Small Cell Lung Cancer

      CBT + HIV Risk Reduction for Social Anxiety

      FES Imaging + Tamoxifen for Breast Cancer

      Elevate Device for Angioplasty

      Probiotics for Ovarian Cancer

      Talazoparib + Enzalutamide for Metastatic Prostate Cancer

      Frequently Asked Questions

      How much do clinical trials in Indiana pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Indiana work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Indiana 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Indiana is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Indiana several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Indiana?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Indiana?

      Most recently, we added Adalimumab + Verapamil for Type 1 Diabetes, LevoCept for Birth Control and Niraparib + Temozolomide for Small Cell Lung Cancer to the Power online platform.